Randomized study evaluating optimal dose, efficacy and safety of E7386 + lenvatinib versus treatment of physicians’ choice in advanced/recurrent endometrial carcinoma previously treated with anti–PD-(L)1 immunotherapy.

Authors: Ramez Nassef Eskander, Jung-Yun Lee, Mansoor Raza Mirza, Domenica Lorusso, Helen Mackay, Isabelle Laure Ray-Coquard, Ana Oaknin, Antonio Gonzalez Martin, Kosei Hasegawa, Bradley Corr, Xiaohua Wu, Alexandra Leary, Tianle Hu, Lea Dutta, Chinyere E Okpara, Jodi McKenzie, Vicky Makker

Published: 2025-05-28

DOI: 10.1200/jco.2025.43.16_suppl.tps5632

Source: Full article

---

Abstract

TPS5632